1. Home
  2. NGNE vs TG Comparison

NGNE vs TG Comparison

Compare NGNE & TG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NGNE
  • TG
  • Stock Information
  • Founded
  • NGNE 2003
  • TG 1988
  • Country
  • NGNE United States
  • TG United States
  • Employees
  • NGNE N/A
  • TG 1500
  • Industry
  • NGNE Biotechnology: Pharmaceutical Preparations
  • TG Metal Fabrications
  • Sector
  • NGNE Health Care
  • TG Industrials
  • Exchange
  • NGNE Nasdaq
  • TG Nasdaq
  • Market Cap
  • NGNE 251.9M
  • TG 291.7M
  • IPO Year
  • NGNE N/A
  • TG 1989
  • Fundamental
  • Price
  • NGNE $21.83
  • TG $8.64
  • Analyst Decision
  • NGNE Buy
  • TG
  • Analyst Count
  • NGNE 6
  • TG 0
  • Target Price
  • NGNE $39.83
  • TG N/A
  • AVG Volume (30 Days)
  • NGNE 224.0K
  • TG 64.3K
  • Earning Date
  • NGNE 05-09-2025
  • TG 08-06-2025
  • Dividend Yield
  • NGNE N/A
  • TG N/A
  • EPS Growth
  • NGNE N/A
  • TG N/A
  • EPS
  • NGNE N/A
  • TG N/A
  • Revenue
  • NGNE $925,000.00
  • TG $617,839,000.00
  • Revenue This Year
  • NGNE N/A
  • TG N/A
  • Revenue Next Year
  • NGNE N/A
  • TG N/A
  • P/E Ratio
  • NGNE N/A
  • TG N/A
  • Revenue Growth
  • NGNE N/A
  • TG 17.42
  • 52 Week Low
  • NGNE $6.88
  • TG $4.31
  • 52 Week High
  • NGNE $74.49
  • TG $9.22
  • Technical
  • Relative Strength Index (RSI)
  • NGNE 62.53
  • TG 62.83
  • Support Level
  • NGNE $16.62
  • TG $8.30
  • Resistance Level
  • NGNE $18.90
  • TG $8.52
  • Average True Range (ATR)
  • NGNE 2.06
  • TG 0.24
  • MACD
  • NGNE 0.38
  • TG 0.00
  • Stochastic Oscillator
  • NGNE 60.81
  • TG 87.69

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About TG Tredegar Corporation

Tredegar Corp, through its subsidiaries, engages in the manufacture of polyethylene plastic films, polyester films, and aluminum extrusions. Polyethylene plastic films produce plastic films, elastics, and laminate materials that are used in personal care products, surface protection films, and specialty and optical lighting applications. The company operates through segments including PE films, flexible packaging films, and aluminum extrusions. Aluminum extrusions generate the majority of revenue and provide high-quality, soft-alloy, medium-strength aluminum utilized in the building and construction, automotive, consumer durables, machinery and equipment, electrical, and distribution markets. Revenue is generated from the United States, Asia, and Brazil.

Share on Social Networks: